P. Van Rooy

1.1k total citations
18 papers, 879 citations indexed

About

P. Van Rooy is a scholar working on Infectious Diseases, Pharmacology and Physiology. According to data from OpenAlex, P. Van Rooy has authored 18 papers receiving a total of 879 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 4 papers in Pharmacology and 4 papers in Physiology. Recurrent topics in P. Van Rooy's work include Antifungal resistance and susceptibility (4 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Pain Mechanisms and Treatments (2 papers). P. Van Rooy is often cited by papers focused on Antifungal resistance and susceptibility (4 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Pain Mechanisms and Treatments (2 papers). P. Van Rooy collaborates with scholars based in Belgium, South Africa and United States. P. Van Rooy's co-authors include G. Cauwenbergh, J. Heykants, R. Woestenborghs, A. Van Peer, J. Van Cutsem, W. Meuldermans, Karel Lavrijsen, Vera Van de Velde, H. Degreef and Robert Woestenborghs and has published in prestigious journals such as Diabetologia, Journal of the American Academy of Dermatology and Drugs.

In The Last Decade

P. Van Rooy

18 papers receiving 818 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. Van Rooy Belgium	9	446	402	92	90	89	18	879
Vera Van de Velde Belgium	12	553 1.2×	464 1.2×	113 1.2×	111 1.2×	102 1.1×	20	1.1k
Richard Hector United States	9	532 1.2×	555 1.4×	115 1.3×	41 0.5×	23 0.3×	15	1.1k
S. J. Roffey United Kingdom	8	269 0.6×	412 1.0×	54 0.6×	125 1.4×	45 0.5×	12	715
S. Jevons United Kingdom	10	259 0.6×	312 0.8×	45 0.5×	32 0.4×	18 0.2×	21	630
J.Chris Jensen Germany	16	218 0.5×	172 0.4×	90 1.0×	334 3.7×	32 0.4×	24	1.0k
Tawfique K. Daneshmend United Kingdom	10	176 0.4×	177 0.4×	33 0.4×	130 1.4×	34 0.4×	14	544
S. G. Jezequel United Kingdom	8	126 0.3×	244 0.6×	36 0.4×	112 1.2×	42 0.5×	12	596
T C Hardin United States	8	256 0.6×	334 0.8×	77 0.8×	47 0.5×	27 0.3×	15	537
Jodi M. Lestner United Kingdom	16	450 1.0×	567 1.4×	64 0.7×	15 0.2×	23 0.3×	18	818
John Ling United States	16	159 0.4×	347 0.9×	17 0.2×	99 1.1×	14 0.2×	50	1.1k

Countries citing papers authored by P. Van Rooy

Since Specialization

Citations

This map shows the geographic impact of P. Van Rooy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Van Rooy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Van Rooy more than expected).

Fields of papers citing papers by P. Van Rooy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Van Rooy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Van Rooy. The network helps show where P. Van Rooy may publish in the future.

Co-authorship network of co-authors of P. Van Rooy

This figure shows the co-authorship network connecting the top 25 collaborators of P. Van Rooy. A scholar is included among the top collaborators of P. Van Rooy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Van Rooy. P. Van Rooy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Weets, Ilse, Bart Van Der Auwera, J. De Schepper, et al.. (2006). Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes. Diabetologia. 49(6). 1158–1162. 16 indexed citations

Hantson, L., Luc Tritsmans, R. Crabbé, J. Gheuens, & P. Van Rooy. (1997). The safety and tolerability of single intravenous doses of lubeluzole (Prosynap) in healthy volunteers.. PubMed. 35(11). 491–5. 2 indexed citations

Heykants, J, et al.. (1996). Effect of Food on the Pharmacokinetics of a New Hydroxypropyl‐β‐Cyclodextrin Formulation of Itraconazole. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 16(3). 424–428. 80 indexed citations

Heykants, J, et al.. (1996). Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole.. PubMed. 16(3). 424–8. 97 indexed citations

Iddekinge, B. Van, G Justus Hofmeyr, W. R. Bezwoda, A A Wadee, & P. Van Rooy. (1993). Recurrent Spontaneous Abortion: Histocompatibility Between Partners, Response to Immune Therapy, and Subsequent Reproductive Performance. American Journal of Reproductive Immunology. 30(1). 37–44. 8 indexed citations

Weber, Christian, Johan Beetens, F. Tegtmeier, et al.. (1992). Ridogrel Inhibits Systemic and Renal Formation of Thromboxane A2 and Antagonizes Platelet Thromboxane A2/Prostaglandin Endoperoxide Receptors upon Chronic Administration to Man. Thrombosis and Haemostasis. 68(2). 214–220. 4 indexed citations

Rooy, P. Van, et al.. (1992). The Antihypertensive and Cardiac Hemodynamic Effects of Nebivolol. Angiology. 43(5). 369–377. 7 indexed citations

Macleod, A F, A J Boulton, D. R. Owens, et al.. (1992). A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group.. PubMed. 18(1). 14–20. 20 indexed citations

Rooy, P. Van, Luc Van Nueten, & J. De Crée. (1991). Nebivolol. Clinical Drug Investigation. 3(S1). 174–175. 5 indexed citations

10.

Rooy, P. Van & J. De Crée. (1991). Haemodynamic Effects of Nebivolol in Poor and Extensive Metabolisers. Clinical Drug Investigation. 3(S1). 161–163. 2 indexed citations

11.

Bruynseels, J., R. De Coster, P. Van Rooy, et al.. (1990). R 75251, a new inhibitor of steroid biosynthesis. The Prostate. 16(4). 345–357. 50 indexed citations

12.

Wouters, Walter, R. De Coster, Robert W. Tuman, et al.. (1989). Aromatase inhibition by R 76713: Experimental and clinical pharmacology. Journal of Steroid Biochemistry. 34(1-6). 427–430. 31 indexed citations

13.

Heykants, J., A. Van Peer, Vera Van de Velde, et al.. (1989). The Clinical Pharmacokinetics of Itraconazole: An Overview. Mycoses. 32(s1). 67–87. 329 indexed citations

14.

Cauwenbergh, G., et al.. (1988). Pharmacokinetic profile of orally administered itraconazole in human skin. Journal of the American Academy of Dermatology. 18(2). 263–268. 213 indexed citations

15.

Leeuw, Ivo H. De, et al.. (1987). Clinical Experience with Cyclandelate in Insulin-Dependent Diabetic Patients with Neuropathy. Drugs. 33(Supplement 2). 125–130. 2 indexed citations

16.

Rooy, P. Van, et al.. (1985). Evaluation of the effect of atenolol on the reaction time of healthy volunteers. European Journal of Clinical Pharmacology. 28(S1). 105–107. 5 indexed citations

17.

Kains, Jean-Pierre, et al.. (1983). Exertional Heat Stress Disease. Acta Clinica Belgica. 38(5). 315–323. 5 indexed citations

18.

Leeuw, I. De, et al.. (1981). Bone mass in obese, goldthioglucose-treated, hyperglycaemic mice. Diabetologia. 20(2). 145–147. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact